Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
ESMO Virtual Plenary: December 2021
Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
- Start date
- 16 Dec 2021
- End date
- 17 Dec 2021
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Programme
Thursday, 16 December 2021
19:30-20:30 CET
Welcome and introduction, Scientific background and context
Andrés Cervantes, Hospital Clinico Universitario de Valencia, Valencia, Spain
Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Thierry André, Hôpital Saint-Antoine, Paris, France
Critical analysis and perspectives
Demetris Papamichael, Bank of Cyprus Oncology Centre, Nicosia, Cyprus
Discussion and Q&A (i)
Faculty and online audience
Friday, 17 December 2021
13:00-14:10 CET / 14:00-15:10 EET / 17:30-18:40 IST / 20:00-21:10 CST / 21:00-22:10 JST
Virtual Plenary Expert Insights: Webcast of 16 December presentations, Discussion and Q&A (ii)
Faculty and online audience
Chair: Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa, Japan
Thierry André, Hôpital Saint-Antoine, Paris, France
Demetris Papamichael, Bank of Cyprus Oncology Centre, Nicosia, Cyprus
Li-Tzong Chen, National Health Research Institutes - National Institute of Cancer Research, Tainan City, Taiwan
Miriam Koopman, UMC - University Medical Center Utrecht, Utrecht, Netherlands
Smruti Koppikar, Bombay Hospital and Medical Research Center, Mumbai, India
